Cost-utility model of brivaracetam in the adjunctive treatment of patients with epilepsy in Spain.

Objective: This study aims to assess the cost utility of Brivaracetam compared with the third-generation anti-epileptic drugs used as standard care.

Methods: A cost utility analysis of Brivaracetam was carried out with other third-generation comparators. The treatment pathway of a hypothetical cohort over a period of 2 years was simulated using the Markov model. Data for effectiveness and the QALYs of each health status for epilepsy, as well as for the disutilities of adverse events of treatments, were analyzed through a studies review. The cost of the anti-epileptics and the use of medical resources linked to the different health statuses were taken into consideration. A probabilistic sensitivity analysis was performed using a Monte Carlo simulation.

Results: Brivaracetam was shown to be the dominant alternative, with Incremental Cost Utility Ratio (ICUR) values from -11,318 for Lacosamide to -128,482 for Zonisamide. The probabilistic sensitivity analysis validates these results. The ICUR sensitivity is greater for increases in the price of Brivaracetam than for decreases, and for Eslicarbizapine over the other adjunctives considered in the analysis.

Conclusions: Treatment with Brivaracetam resulted in cost effective and incremental quality adjusted life years come at an acceptable cost.